Latest Breaking News On - Kevin heyries - Page 1 : comparemela.com

(0) Three-target, multi-year collaboration includes the development of bispecific antibodies to treat sight-threatening complication of type 1 and 2 diabetes AbCellera (Nasdaq: ABCL) and Angios GmbH (Angios) announced today that they have entered into a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy. Through this collaboration, Angios can focus on advancing their unique scientific insights for treating blindness in diabetes, rather than on establishing and scaling internal antibody discovery capabilities, said Carl Hansen, Ph.D., CEO and President of AbCellera. We are excited to work closely with Angios to start their programs without delay, including identifying bispecific antibodies against diabetic retinop

Jessica yinglingGregor wickAngios gmbhJosef penningerKevin heyriesCarl hansenExchange commissionAbcellera biologics incBusiness developmentPrivate securities litigation reform actFinancial conditionDiabetic retinopathy progressionCurr diabetesAbcellera biologicsCellera inquiriesஜெசிகா யிங்லிங்